Literature DB >> 33520078

Thrombocytopenia induced by glycoprotein (GP) IIb-IIIa antagonists: about two cases.

Salma Abdeladim1, Mahassine Elharras1, Amal Elouarradi1, Ilham Bensahi1, Sara Oualim1, Fatimazahra Merzouk1, Mohamed Sabry1.   

Abstract

In this paper, we report two cases of induced thrombocytopenia after the infusion of glycoprotein (GP) IIb/IIIa receptors antagonists, following a coronary angioplasty. The first patient is a 65-year-old woman, admitted with acute coronary syndrome requiring percutaneous angioplasty with stenting. The patient was given tirofiban + unfractionated heparin (UFH). Ten hours later, the patient revealed very severe thrombocytopenia and went into hemorrhagic shock (hematemesis and hematoma at the injection site). The patient was transfused with nine units of red blood cells (RBCs), 24 platelets pellets and 4 units of fresh frozen plasma (FFP). The second patient is a 76-year-old woman. She was admitted to hospital for acute coronary syndrome necessitating percutaneous angioplasty with stenting and a glycoprotein IIb/IIIa receptor antagonists, tirofiban + unfractionated (UFH). Four hours later, the patient presented with gingivorrhagia associated thrombocytopenia. She received six platelet pellets transfusion with well clinical and biological improvement. These two observations raise the significance of a close monitoring of platelet count after the initiation of GP IIb/IIIa antagonists infusion, which are sometimes responsible for life-threatening adverse events. Copyright: Salma Abdeladim et al.

Entities:  

Keywords:  Glycoprotein IIb/IIIa receptor antagonist; case report; thrombocytopenia; tirofiban

Mesh:

Substances:

Year:  2021        PMID: 33520078      PMCID: PMC7825373          DOI: 10.11604/pamj.2021.38.9.27215

Source DB:  PubMed          Journal:  Pan Afr Med J


  15 in total

Review 1.  Frequency and management of thrombocytopenia with the glycoprotein IIb/IIIa receptor antagonists.

Authors:  Lindsay M Huxtable; Mohammad J Tafreshi; Amol N S Rakkar
Journal:  Am J Cardiol       Date:  2005-12-01       Impact factor: 2.778

2.  Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis.

Authors: 
Journal:  Circulation       Date:  1997-09-02       Impact factor: 29.690

Review 3.  Progress in the development of antiplatelet agents: Focus on the targeted molecular pathway from bench to clinic.

Authors:  Qian Xiang; Xiaocong Pang; Zhenming Liu; Guoping Yang; Weikang Tao; Qi Pei; Yimin Cui
Journal:  Pharmacol Ther       Date:  2019-07-26       Impact factor: 12.310

4.  A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.

Authors: 
Journal:  N Engl J Med       Date:  1998-05-21       Impact factor: 91.245

5.  Profound thrombocytopenia induced by clopidogrel with a prior history of long-term safe administration.

Authors:  Yuan-Lin Guo; Jian-Jun Li; Jin-Qing Yuan; Xue-Wen Qin; Xin Zheng; Chao-Wei Mu; Yi-Hong Hua
Journal:  World J Cardiol       Date:  2010-06-26

6.  Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy.

Authors:  D C Sane; L V Damaraju; E J Topol; C F Cabot; M A Mascelli; R A Harrington; M L Simoons; R M Califf
Journal:  J Am Coll Cardiol       Date:  2000-07       Impact factor: 24.094

7.  Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa.

Authors:  Daniel W Bougie; Peter R Wilker; Elizabeth D Wuitschick; Brian R Curtis; Mohammad Malik; Stewart Levine; Richard N Lind; Jaime Pereira; Richard H Aster
Journal:  Blood       Date:  2002-09-15       Impact factor: 22.113

8.  Nonpeptide glycoprotein IIb/IIIa inhibitors. 5. Antithrombotic effects of MK-0383.

Authors:  J J Lynch; J J Cook; G R Sitko; M A Holahan; D R Ramjit; M J Mellott; M T Stranieri; I I Stabilito; G Zhang; R J Lynch
Journal:  J Pharmacol Exp Ther       Date:  1995-01       Impact factor: 4.030

Review 9.  Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors.

Authors:  R H Aster; B R Curtis; D W Bougie; S Dunkley; A Greinacher; T E Warkentin; B H Chong
Journal:  J Thromb Haemost       Date:  2006-03       Impact factor: 5.824

10.  2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).

Authors:  Marco Roffi; Carlo Patrono; Jean-Philippe Collet; Christian Mueller; Marco Valgimigli; Felicita Andreotti; Jeroen J Bax; Michael A Borger; Carlos Brotons; Derek P Chew; Baris Gencer; Gerd Hasenfuss; Keld Kjeldsen; Patrizio Lancellotti; Ulf Landmesser; Julinda Mehilli; Debabrata Mukherjee; Robert F Storey; Stephan Windecker
Journal:  Eur Heart J       Date:  2015-08-29       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.